BioSapien
BioSapien, founded in 2018, pioneers minimally invasive drug delivery platforms with its signature MediChip™ technology, utilizing 3D printing to deliver targeted chemotherapy directly to tumor sites to minimize side effects.
- CEO / Founder
- Khatija Ali
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $10.6M
- Latest Round
- Pre-Series A
- Key Investors
- Global Ventures, Dara Holdings, RebelBio/IndieBio, Globivest, JPIN, SOSV, Hikma Ventures, Golden Gate Ventures
Technology & Products
Key Products
MediChip™: A 3D-printed, slow-release, biocompatible implantable patch designed to deliver targeted chemotherapy directly to tumor sites, minimizing side effects and enhancing treatment efficacy.
Technological Advantage
Ability to minimize systemic side effects and enhance treatment precision through targeted drug delivery.
Differentiation
Value Proposition
Targeted delivery of chemotherapy directly to tumors, minimizing side effects and enhancing treatment efficacy.
How They Differentiate
BioSapien differentiates itself through its focus on 3D-printed chemotherapy delivery via its MediChip™ technology, enabling targeted treatment directly to tumors, minimizing side effects, and enhancing treatment efficacy, unlike competitors who concentrate on diagnostics or genomics.
Market & Competition
Target Customers
Cancer patients seeking reduced systemic side effects from chemotherapy.
Industry Verticals
["Biotech","Healthcare","Oncology"]
Competitors
PanTher Therapeutics, scPharmaceuticals, Vaxxas, Valeritas
Growth & Milestones
Growth Metrics
Preparing for clinical trials with a goal to treat 1 million patients by 2035
Major Milestones
["Global patent issuance for MediChip","Accepted into HUB71 Cohort 13","Preparing for human clinical trials"]
Notable Customers
IROS